Home >Companies >Dr Reddy’s reaches 3rd stage of trial of anti-diabetic drug

Dr Reddy’s reaches 3rd stage of trial of anti-diabetic drug

Dr Reddy’s reaches 3rd stage of trial of anti-diabetic drug

Hyderabad: Dr Reddy’s Laboratories on Friday said it has reached the third stage of clinical trial for an anti-diabetic drug, which could become the first innovative molecule from India.

The company also said it has completed the first stage of human trials for an anti-cholesterol compound with promising results.

The anti-diabetic compound ‘Balagletazone´ has reached phase III clinical trial stage and has the “potential to become the first innovative molecule from India," Dr Reddy’s Laboratories founder K Anji Reddy told reporters here today.

He said the company is also working on a new cholesterol lowering compound.

“We are developing an anti-cholesterol compound, which is showing a very promising potential. We have just concluded our Phase I clinical trials," Reddy said.

He, however, did not specify where the trials are being done and by when it could go to the next stage.

Phase I clinical trials are the first stage of testing in human subjects on a select small number of volunteers (20-50), while the phase III trials are conducted on larger randomized sample of up to 3,000.

He claimed that the new anti-cholesterol compound has the potential of becoming a blockbuster drug and many other multinational firms were also working on it.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
My Reads Redeem a Gift Card Logout